![]() |
||||||||||||
| NPRI Reports Record First Quarter Earnings | ||||||||||||
Las Vegas, NV (April 20, 2006) - Nutri Pharmaceuticals Research, Inc. today reported first quarter 2006 results from operations. Sales approximated $421,000 as compared to $290,000 in first quarter of the prior year. Gross profit approximated $339,000 as compared to $207,000 in same period of the prior year. Operating expenses approximated $281,000 as compared to $179,000. Overall net income approximated $42,000 as compared to $11,000 in the same period of the prior year. Commenting on the results, Chief Executive Officer and President Godfrey Yew said,“We are thrilled to have concluded our best quarter results. Our performance this quarter reflects the sustained momentum we generated from our business development efforts during 2005. We have negotiated more favorable contracts and have been able to reduce our overall operating expenses.” About NPRI
At the heart of its oil powders is the O2P Oil-to-Powder technology. This patent pending process converts most edible oils, gels or pastes into a free-flowing powder without affecting the isomeric structure, fatty acid profile, color, taste or aroma of the base oil. O2P does not rely on traditional techniques that utilize extremes in heat or cold, or micro-encapsulation technology. The company currently offers more than 50 shelf-stable powders. The company can also apply O2P technology to a third-party’s oil, paste or gel through an arrangement called tolling. Based in Las Vegas, Nevada USA, the company has representative sales offices near Chicago, Amsterdam, Guatemala City and Bangkok. Nutri Pharmaceuticals Research, Inc. shares are currently traded in the United States on the “NQB (National Quotation Bureau) Pinksheets” under the symbol NRPR.PK. Forward Looking Statement |
||||||||||||
NPRI • 6780 Caballo Street • Las Vegas, NV 89119• USA Email: info@o2pus.com • Tel: +1 (702) 309 8627 • Fax: +1 (702) 309 8630 • Toll Free: 1 800 838 9736 O2P™ is a registered trademark of NPRI ©1994 - 2006 Nutri Pharmaceuticals Research, Inc. (NPRI) |
||||||||||||